Trial for People With Established Type 2 Diabetes During Ramadan

NCT02292290 on ClinicalTrials.gov · last registry update 2020-01-30

Finished December 2012, after enrolling 99 people. Primary outcome, as filed: Composite. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Leicester
Sponsor type: Other
Enrollment: 99
Started: 2011-04
Primary completion: 2012-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Composite

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.